SRPTSarepta Therapeutics, Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, heavy debt (CCC), and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -93% · now 27% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SRPT take a bad year?
The deepest fall in SRPT's price history on file is −93%; it is 27% below its high today.
Net debt · as at Q2 2026 · debt less the cash on hand, with no positive EBITDA to service it
- Altman Z-score
- -1.10
Altman Z-score · distress zone, below 1.8
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 88%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $848M
- Cash and short-term investments
- $788M
- Net debt
- $59M
- EBITDA, trailing twelve months
- −$126M
- Operating profit, trailing twelve months
- −$143M
- Debt / equity
- 0.56×
- Annualised volatilitytwo years of daily moves
- 88%
- Worst drawdown on file
- −93%
- Below its 52-week high
- 27%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.